Abstract
Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 600-606 |
| Number of pages | 7 |
| Journal | Cancer |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1966 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Hepatotoxic effects of methotrexate'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS